Where is Embecta located?

Embecta is headquartered in Parsippany, United States.

How many employees does Embecta have?

As of Apr 30, 2026, the latest employee count at Embecta is 1146.

Is Embecta a funded company?

Embecta is a funded company, having raised a total of $***** in its 1st and only funding round.

What is the annual revenue of Embecta?

Annual revenue of Embecta is $1.08B as on Sep 30, 2025.

Where does Embecta rank among its competitors?

Embecta ranks 7th amongst 59 active competitors, of which 11 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Kaleido, which secured $13M in Jan, 2026.

Who are the top competitors of Embecta?

Embecta's top competitors include Tandem Diabetes, Insulet and Kaleido. Among them, Kaleido secured the most recent funding round in January, 2026.

Embecta - 2026 Company Profile, Competitors & Financials

Embecta is a public company based in Parsippany (United States), founded in 2022. It operates as a Manufacturer of insulin delivery solutions, including pen needles and insulin syringes. The company has 59 active competitors, including 11 funded and 17 that have exited. Its top competitors include companies like Tandem Diabetes, Insulet and Kaleido.

Company Details

Manufacturer of insulin delivery solutions, including pen needles and insulin syringes. The company provides solutions focused on improving the lives of people with diabetes. It develops and provides solutions that make life better for people with diabetes, advancing innovation in insulin delivery to improve the injection experience. The company also provides access to education and resources on proper injection technique.

Website: www.embecta.com
Social
Email ID: *****@embecta.com
Phone Number: +1 **********

Key Metrics

Founded Year

2022

Location

Parsippany, United States

Stage

Public

Ranked

7^th among 59 active competitors

Annual Revenue

$1.08B as on Sep 30, 2025

Employee Count

1,146 as on Apr 30, 2026

Investment & Acquisitions

Owen Mumford

Similar Companies

Insulet & 37 more

Exit Details

Public

View Embecta's full profile

Embecta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EMBECTA CORP. CIN: 1872789 , United States, Active	Jul 07, 2021	$1.08B (As on Sep 30, 2025)	2100 (As on Sep 30, 2024)	-

Embecta got listed on Mar 22, 2022.

Click here to take a look at Embecta's IPO in detail

Embecta has not raised any funding rounds yet.

Embecta's employee count trend

Embecta has 1,146 employees as of Apr 26. Here is Embecta's employee count trend over the years:

Uncover Embecta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Embecta include Tandem Diabetes, Insulet and Kaleido. Here is the list of Top 10 competitors of Embecta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tandem Diabetes 2008, San Diego (United States), Public	Developer of devices for continuous glucose monitoring and manual insulin delivery	$101M	Gynther Capital, Domain Associates & 5 others	77/100
2nd	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	77/100
3rd	Kaleido 2013, Utrecht (Netherlands), Series D	Developer of insulin therapy for treating diabetes	$183M	Life Sciences Partners, Inkef & 10 others	64/100
4th	Ypsomed 2003, Burgdorf (Switzerland), Acquired	Developer of self delivery injection systems and diabetes care systems	$7.45M	BV Partners, BV Group	62/100
5th	Sigrid Therapeutics 2014, Stockholm (Sweden), Series C	Developer of therapies to treat metabolic and chronic lifestyle diseases	$27M	Irrus Investments, Joyance Partners & 9 others	61/100
6th	Microtech Medical 2011, Hangzhou (China), Public	Medical devices developer for diabetes care	$88.2M	Tencent, IDG Capital & 9 others	58/100
7th	Embecta 2022, Parsippany (United States), Public	Manufacturer of insulin delivery solutions, including pen needles and insulin syringes	-	-	53/100
8th	Modular Medical 2017, San Diego (United States), Series A	Developer of insulin pump for insulin delivery	$5.28M	-	52/100
9th	Medtronic Diabetes 1993, Northridge (United States), Unfunded	Diabetes management solutions: insulin pumps, smart pens, and continuous glucose monitoring	-	-	49/100
10th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	48/100